Comparative evaluation of clinical and economic efficiency of paliperidone in various dosage forms used in patients with schizophrenia

Abstract

In view of the influence on the budget, all forms of paliperidone have similar pharmacoeconomic efficacy with the advantage of prolonged release injectable (depot) forms that increase patient's adherence to treatment. As a result, CUR of injectable forms was lower compared to that of the peroral form by 11,1 and 46,3% of month and 3-month forms, respectively. ICUR for paliperidone used once in 3 month (trevicta) was more effective compared to paliperidone used monthly (xeplion). It has been concluded that paliperidone for prolonged release injections used once in 3 month is most pharmacoeconomically effective.

Revisiting Drug Compliance: The Need for a Holistic Approach in the Treatment of Severe Mental Disorders

“…However, despite the general consensus on the described strategy, 1 the practice of using prolonged-release antipsychotics in various healthcare institutions remains inconsistent and, even taking into account the greater cost, is unreasonably limited. 2 Among the barrier factors for the widespread use of depot drugs in clinical work are organizational factors (a limited number of drugs paid for from insurance funds due to a high cost for depot antipsychotics), the doctors` attitude (difficulties in dose control, subjective perception of the appointment as coercion of the patient, established clinical practice), or factors related to the patient, such as a fear of painful injections, lack of information or perception of depot therapy as a coercive measure. 3 At the same time, an analysis of the frequency of prolongedrelease antipsychotics use indicates their predominant prescription in situations of clinical uncertainty: among 37.8% of patients with polypharmacy, 4 as well as among those with increased aggressiveness 5 and those who rarely seek in-patient care.…”